A detailed history of First Light Asset Management, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, First Light Asset Management, LLC holds 943,611 shares of CRNX stock, worth $50.6 Million. This represents 4.2% of its overall portfolio holdings.

Number of Shares
943,611
Previous 1,200,508 21.4%
Holding current value
$50.6 Million
Previous $53.8 Million 10.36%
% of portfolio
4.2%
Previous 4.9%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$43.83 - $54.98 $11.3 Million - $14.1 Million
-256,897 Reduced 21.4%
943,611 $48.2 Million
Q2 2024

Aug 14, 2024

SELL
$42.12 - $51.91 $20.6 Million - $25.4 Million
-489,669 Reduced 28.97%
1,200,508 $53.8 Million
Q1 2024

May 15, 2024

SELL
$34.76 - $46.81 $10.3 Million - $13.9 Million
-297,595 Reduced 14.97%
1,690,177 $79.1 Million
Q4 2023

Feb 14, 2024

BUY
$25.62 - $37.07 $11 Million - $16 Million
430,550 Added 27.65%
1,987,772 $70.7 Million
Q2 2023

Aug 14, 2023

SELL
$15.73 - $23.6 $973,734 - $1.46 Million
-61,903 Reduced 3.82%
1,557,222 $28.1 Million
Q1 2023

May 15, 2023

BUY
$15.31 - $21.1 $4.44 Million - $6.12 Million
289,812 Added 21.8%
1,619,125 $26 Million
Q4 2022

Feb 14, 2023

SELL
$15.49 - $19.05 $268,581 - $330,307
-17,339 Reduced 1.29%
1,329,313 $24.3 Million
Q3 2022

Nov 14, 2022

BUY
$18.11 - $22.37 $1.92 Million - $2.37 Million
106,043 Added 8.55%
1,346,652 $26.4 Million
Q2 2022

Aug 12, 2022

BUY
$16.49 - $27.64 $10.8 Million - $18.2 Million
657,842 Added 112.88%
1,240,609 $23.1 Million
Q1 2022

May 13, 2022

BUY
$17.15 - $28.31 $5.32 Million - $8.78 Million
309,971 Added 113.63%
582,767 $12.8 Million
Q4 2021

Feb 14, 2022

BUY
$19.35 - $28.41 $5.28 Million - $7.75 Million
272,796 New
272,796 $7.75 Million

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.88B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track First Light Asset Management, LLC Portfolio

Follow First Light Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Light Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on First Light Asset Management, LLC with notifications on news.